Search
Now showing items 11-13 of 13
Prognostic implications of response to neoadjuvant chemotherapy in breast cancer subtypes
(Taylor and Francis Ltd., 2024)
The current study was designed to assess the response to treatment, as well as clinical and survival outcomes, across different breast cancer subtypes in patients who underwent neoadjuvant chemotherapy (NAC). From 2014 to ...
The prognostic role of mismatch repair status and CDX-2 expression with inflammatory markers and pathological risk factors in stage ıı and ııı colon cancer: Multicenter real-life data
(2024)
Objective: Colorectal cancer is common worldwide, and adjuvant treatment’s benefit is still controversial. We designed this study to determine the role of MSI and CDX-2 status determined by immunohistochemistry (IHC) ...
Prognostic significance of HER2 loss after HER2-targeted neoadjuvant treatment in patients with HER2-positive locally advanced breast cancer
(2024)
Loss of human epidermal growth factor receptor 2 (HER2) expression can be seen in almost 25–30 % patients after HER2 receptor directed neoadjuvant treatment. These patients have unclear clinical outcomes in previous studies. ...